FRM6439/7 SARS-CoV-2 Assessment and Screening (in deceased organ donors)

					NF	15	
Ble	0	od a	nd	Trai	nspl	ant	
Effective date: 30/03/2022							

Completion of this form is mandatory for ALL donors as part of the donor characterisation process and must be made available to transplant centres and laboratories, as appropriate.

	Question	Comments/Details
1	Name, DOB, Unit Name	
2	Date and reason for admission to hospital	
	·	
3	Date and time of admission to ICU	
4		
4	Location on admission and subsequent movement in ICU	
	(i.e. side room, open bay)	
5	Chest X Ray/CT	
	Please ensure the Chest X ray/CT is reviewed by the ICU medical team	
	·	
	Any abnormalities to the Chest X ray/CT? Yes No (please give details)	
	, ,	
	Give relevant details in case of changes	
Pre	vious SARS-Cov-2 Infection or Known	Exposure to SARS-CoV-2
6	Any history/previous diagnosis of SARS-Covinfection?	y-2 Symptoms:
	Yes No	
		Date of onset of symptoms:
7	In relation to Q6, was SARS-Cov-2 infection confirmed on RNA testing?	Date of Diagnosis (date of first positive SARS-CoV-2 RNA):
	Yes No N/A	Please also enter available information
		on table in Q16
8	Did this result in a hospital admission?	Date of hospital admission:
	Yes No N/A	
		Date of discharge:

FRM6439/7 SARS-CoV-2 Assessment and Screening (in deceased organ donors)

				NF	15		
Blood and Transplant							
Effective date: 30/03/2022							

9	Please confirm resolution of COVID-19 symptoms including no fever for at least 48 hours (resolving cough and anosmia are acceptable as these may remain for several weeks)	Yes No N/A If 'No' please specify:		
10	Any exposure to a proven case of COVID-19 in the last 10 days? Yes No (check that this was a definitive exposure to someone who was infectious* at the time) *Generally defined as from 48 hours before to around 7-10 days after date of onset of symptoms*	Date of exposure: Nature of exposure: When did the index case test positive?		
11	Other SARS-CoV-2 positive patients in the unit?: Consider Infection, Prevention and Control measures. Include information such as any specific concerns, date of admission and testing undertaken as appropriate. Do NOT record Patient ID Detail (confidentiality)	Yes No If 'Yes' please specify:		
12	Please confirm the ICU team feel COVID-19 has been reasonably excluded (history, exam tests, radiology).	Yes No Any other relevant information, please add to section15		

***If there is a strong clinical suspicion of current COVID-19 as determined by ICU team, then donation should NOT proceed

Vac	Vaccination History						
13	Has COVID-19 vaccine been given? Yes No	1st dose date: Type: 2nd dose date: Type: 3rd dose date: Type: 4th dose date: Type:					
14	If the donor has had an intracranial disaster and	also has low platelets,	haematology a	dvice may be needed.			
	Are the intensive care physicians satisfied that \ Thrombosis and Thrombocytopenia (VITT) has excluded in this donor, where appropriate?		Yes	No			

FRM6439/7 SARS-CoV-2 Assessment and Screening (in deceased organ donors)

				N	15		
Bloc	od a	nd	Trai	nspl	ant		
Effective date: 30/03/2022							

	additiona	l information					
15	15 Any other relevant information?						
CVE	29-CaV-2 F	RNA Results					
16			NA results avai	lable to donation team (including	p pre-admission		
		nese <u>MUST</u> be re			5		
	and Time	Sample Type	Indication for	Details of test results			
Take	en IM/YY 00:00	(NTS/NPA/ETA)	Testing	Assay name and cycle threshold (Ct) value where available (get lab assistance to complete)	Result		
In cases where there is suspicion of exposure to SARS-CoV-2 or positive/borderline SARS-CoV-2 RNA results virologists are asked to provide a clinical interpretation based on information provided in this form. Written interpretation should be provided. For Northern Ireland via Belfast Trust Links Labs system, for all other virology laboratories via secure email. Please ensure the interpretation include 3 points of PID including donor ID							
Failure of internal control amplification invalidates the test – no result available (system failure). The test needs to be repeated on the same or another sample. This is not an indeterminate result.							
Viro	Virologists and transplant teams requiring further information should contact SN as shown below.						
Comp	Completed by						
Name: Specialist Nurse							
Contact number / team pager:							
Email:							